Spiro Rombotis - Cyclacel Pharmaceuticals CEO and President and Executive Director
| CYCC Stock | USD 2.30 0.51 28.49% |
CEO
Mr. Spiro George Rombotis serves as President, Chief Executive Officer, Director of Cyclacel Pharmaceuticals Inc. Mr. Rombotis has served as a director of the Company since March 2006 since 2006.
| Age | 65 |
| Tenure | 18 years |
| Professional Marks | MBA |
| Address | 200 Connell Drive, Berkeley Heights, NJ, United States, 07922 |
| Phone | 908 517 7330 |
| Web | https://www.cyclacel.com |
Spiro Rombotis Latest Insider Activity
Tracking and analyzing the buying and selling activities of Spiro Rombotis against Cyclacel Pharmaceuticals stock is an integral part of due diligence when investing in Cyclacel Pharmaceuticals. Spiro Rombotis insider activity provides valuable insight into whether Cyclacel Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Cyclacel Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cyclacel Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Spiro Rombotis over three months ago Purchase by Spiro Rombotis of 6070 shares of Cyclacel Pharmaceuticals | ||
Spiro Rombotis over six months ago Acquisition by Spiro Rombotis of 110000 shares of Cyclacel Pharmaceuticals subject to Rule 16b-3 | ||
Spiro Rombotis over a year ago Acquisition by Spiro Rombotis of 57600 shares of Cyclacel Pharmaceuticals subject to Rule 16b-3 |
Cyclacel Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.8633) % which means that it has lost $0.8633 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7263) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuticals' management efficiency ratios could be used to measure how well Cyclacel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.43. The current year's Return On Capital Employed is expected to grow to -44.7. At present, Cyclacel Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 23.9 M, whereas Total Assets are forecasted to decline to about 8.4 M.Similar Executives
| Showing other executives | CEO Age | ||
| Gur Roshwalb | Akari Therapeutics PLC | 45 | |
| Jason Okazaki | Assembly Biosciences | 48 | |
| Teofilo MBA | Pulmatrix | 54 | |
| Derek Small | Assembly Biosciences | 41 | |
| Kevin Koch | Edgewise Therapeutics | 64 | |
| Ankit Mahadevia | Spero Therapeutics | 36 | |
| Robert Clarke | Pulmatrix | 46 | |
| Sean McCarthy | CytomX Therapeutics | 51 | |
| David Solomon | Akari Therapeutics PLC | 57 | |
| Teofilo Raad | Pulmatrix | 48 | |
| John McHutchison | Assembly Biosciences | N/A | |
| Ted Raad | Pulmatrix | 48 | |
| Mark Manfredi | Ikena Oncology | 53 | |
| LLM JD | Tempest Therapeutics | 54 | |
| Rachelle Jacques | Akari Therapeutics PLC | 53 | |
Management Performance
| Return On Equity | -2.73 | ||||
| Return On Asset | -0.86 |
Cyclacel Pharmaceuticals Leadership Team
Elected by the shareholders, the Cyclacel Pharmaceuticals' board of directors comprises two types of representatives: Cyclacel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclacel. The board's role is to monitor Cyclacel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cyclacel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclacel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gill Christie, Director Resources | ||
| Samuel Barker, Director | ||
| Christopher Henney, Independent Vice Chairman of the Board | ||
| Gregory Hradsky, Independent Director | ||
| John Banham, Independent Director | ||
| Robert Westwood, Head Devel | ||
| Paul McBarron, COO, CFO, Principal Accounting Officer, Executive VP of Fin. and Admin., Secretary and Executive Director | ||
| Grace Kim, Investor Executive | ||
| Nicholas Bacopoulos, Independent Director | ||
| Lloyd Sems, Independent Director | ||
| David UPrichard, Independent Chairman of the Board | ||
| Judy Chiao, Vice President - Clinical Development and Regulatory Affairs | ||
| Mark MD, Senior Officer | ||
| Robert Spiegel, Independent Director | ||
| Spiro Rombotis, CEO and President and Executive Director | ||
| Brian MD, Interim Director |
Cyclacel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclacel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.73 | ||||
| Return On Asset | -0.86 | ||||
| Operating Margin | (172.90) % | ||||
| Current Valuation | (981.32 K) | ||||
| Shares Outstanding | 1.32 M | ||||
| Shares Owned By Insiders | 7.12 % | ||||
| Shares Owned By Institutions | 16.73 % | ||||
| Number Of Shares Shorted | 24.34 K | ||||
| Price To Earning | (0.40) X | ||||
| Price To Book | 3.82 X |
Pair Trading with Cyclacel Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclacel Stock
| 0.73 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.72 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.66 | ELYM | Eliem Therapeutics | PairCorr |
| 0.54 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (26.75) | Revenue Per Share 0.494 | Return On Assets (0.86) | Return On Equity (2.73) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.